Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Autophagy01:27

Autophagy

5.8K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.8K
Feedback Inhibition00:46

Feedback Inhibition

57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
Enzyme Inhibition01:30

Enzyme Inhibition

91.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.9K
What is Natural Selection?01:32

What is Natural Selection?

128.1K
Natural selection is an evolutionary process in which individuals with survival-promoting traits reproduce at higher rates. These favorable traits become more common within a population or species. Naturally selected traits initially arise via random genetic mutations. In order for selection to occur, there must be variation within a population, the trait controlling the variation must be heritable, and there must be an evolutionary advantage for variation in the trait.
128.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Correction to "Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP)".

ACS medicinal chemistry letters·2026
Same author

Stepwise Differentiation of Mouse Embryonic Stem Cells Into Murine Blood Vessel Organoids With Endothelial Lineage Tracing for Quality Control.

Bio-protocol·2026
Same author

Development and reliability testing of BRANT-MERQS-2A: A quality assessment tool for medication review type 2a reports.

International journal of clinical pharmacy·2026
Same author

The INSPIRE doctoral network in safety pharmacology - Looking back and ahead.

Journal of pharmacological and toxicological methods·2026
Same author

Binding Mechanism of UAMC-1110 to Fibroblast Activation Protein.

Journal of chemical information and modeling·2026
Same author

Identification of small-molecule autophagy activators via GFP-LC3 high-throughput screening and a cargo-based autophagy flux and processing assay.

European journal of pharmacology·2026

関連する実験動画

Updated: Jan 28, 2026

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.4K

Vectorized ULK1/2およびVPS34阻害剤による腫瘍選択的オートファジー阻害剤の開発

Lorenzo Cianni1, Kathryn Jacobs2,3, Sergei Grintsevich1

  • 1Laboratory of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp, 2610 Wilrijk, Belgium.

Journal of medicinal chemistry
|January 26, 2026
PubMed
まとめ

研究者らは、がん細胞の生存メカニズムを選択的に阻害するための新規腫瘍標的オートファジー阻害剤を開発した。これらの化合物は、健康な組織を温存しながら腫瘍のオートファジーを選択的に阻害することにより、がん治療に有望であることを示している。

キーワード:
オートファジー阻害剤腫瘍標的療法ULK1ULK2VPS34がん治療分子標的薬

さらに関連する動画

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

1.5K
Activating Autophagy by Aerobic Exercise in Mice
08:44

Activating Autophagy by Aerobic Exercise in Mice

Published on: February 3, 2017

12.7K

関連する実験動画

Last Updated: Jan 28, 2026

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.4K
Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

1.5K
Activating Autophagy by Aerobic Exercise in Mice
08:44

Activating Autophagy by Aerobic Exercise in Mice

Published on: February 3, 2017

12.7K

科学分野:

  • 分子生物学
  • 細胞生物学
  • がん研究

背景:

  • オートファジーは、生存と恒常性にとって重要な主要な細胞プロセスです。
  • 腫瘍は、可塑性、適応、および治療耐性のためにオートファジーを利用しており、治療標的となっています。
  • 健康な組織におけるその重要な役割のため、腫瘍における選択的なオートファジー阻害が不可欠です。

研究 の 目的:

  • 腫瘍標的オートファジー阻害剤の設計と検証。
  • がん細胞におけるオートファジー開始因子（ULK1/2およびVPS34）を選択的に阻害する化合物の開発。
  • 腫瘍学における新規治療戦略の探求。

主な方法:

  • 腫瘍標的ベクターを用いたオートファジー開始因子阻害剤（ULK1/2およびVPS34）の設計。
  • RGR配列標的ペプチドと組み合わせた低ナノモルULK1/2阻害性スキャフォールドを利用。
  • invitro、in_cellulo、およびinvivoの前臨床モデルを通じて化合物を検証しました。

主要な成果:

  • 有望な腫瘍標的オートファジー阻害剤を開発しました。
  • 前臨床モデルにおいて、これらの化合物の選択的な活性を実証しました。
  • 腫瘍特異的オートファジーを標的とする阻害剤の保存された有効性を示しました。

結論:

  • 開発された化合物は、腫瘍標的オートファジー阻害剤の最初の例です。
  • これらの阻害剤は、オートファジーの組織特異的な調節のための新しいアプローチを提供します。
  • オートファジー調節を必要とする腫瘍学およびその他の分野に応用可能性があります。